Abbott Laboratories (ETR:ABL)
Germany
· Delayed Price · Currency is EUR | Market Cap | 209.46B |
| Revenue (ttm) | 40.52B |
| Net Income (ttm) | 12.90B |
| Shares Out | n/a |
| EPS (ttm) | 7.38 |
| PE Ratio | 16.24 |
| Forward PE | n/a |
| Dividend | 2.10 (1.71%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 127 |
| Average Volume | 519 |
| Open | 121.06 |
| Previous Close | 121.06 |
| Day's Range | 121.06 - 122.96 |
| 52-Week Range | 90.00 - 134.14 |
| Beta | 0.69 |
| RSI | 50.77 |
| Earnings Date | Apr 16, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrica...
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE: ABT). And retail traders should know. We noticed this today when the trades showed up on publicly avai...
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary In...
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...
What Does the Market Think About Abbott Laboratories?
Abbott Laboratories's (NYSE: ABT) short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.93 million shares sold short , which is 1.33% of all regula...
Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees
Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a buy with a price target of $145-$160.
Abbott Laboratories Basking In A Sharp Turn In Sentiment
Recent Report Shows That Sen. Shelley M Capito Sold Up to $75K Worth of Comcast Stock
March 6, 2025 records indicate that Senator Shelley M Capito filed a sale of Comcast (NASDAQ: CMCSA), valued between $5,005 and $75,000. According to the March filing, the transaction occurred on Mar...
Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock
March 6, 2025 records indicate that Representative Jared Moskowitz filed a sale of West Pharmaceutical Servs (NYSE: WST), valued between $1,001 and $15,000. According to the March filing, the transac...
Strong Earnings Lift Abbott Laboratories Shares
Health care company Abbott Laboratories (ABT) increases sales, earnings around the globe.
The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval...
In law violation, baby formula co sponsors meet of paediatricians
Abbott Nutrition is sponsoring a national paediatrics summit in Dehradun, despite laws prohibiting baby food manufacturers from funding medical conferences. The Indian Academy of Paediatrics had previ...
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul ...
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new or...
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the l...
Unlocking Intrinsic Value: Analysis of Abbott Laboratories
Unlocking Intrinsic Value: Analysis of Abbott Laboratories
Abbott Laboratories closes flat after six sessions of gains
Abbott Laboratories (ABT) sees mixed momentum as shares dip after gains. Analysts highlight strong demand, low debt, and dividend growth.
My Best Dividend Aristocrats For March 2025
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the l...
Abbott Laboratories: An Exploration into Its Intrinsic Value
Abbott Laboratories: An Exploration into Its Intrinsic Value
Abbott Laboratories Declares 405th Consecutive Quarterly Dividend
Abbott Laboratories Declares 405th Consecutive Quarterly Dividend
Abbott Declares 405th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
On Thursday, Dexcom, Inc.'s (NASDAQ: DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion . U.S. revenue rose by 4%, while i...
Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know
February 11, 2025 records indicate that Representative Emily Randall filed a sale of Abbott Laboratories (NYSE: ABT), valued between $11,011 and $165,000. According to the February filing, the transa...
Looking Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE: ABT) short percent of float has risen 4.82% since its last report. The company recently reported that it has 14.97 million shares sold short , which is 0.87% of all regul...